Related references
Note: Only part of the references are listed.Proton pump inhibitors use and the risk of fatty liver disease: A nationwide cohort study
Jeung Hui Pyo et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2021)
Proton pump inhibitors use and dementia risk: a meta-analysis of cohort studies
Yun Zhang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2020)
461 PROTON PUMP INHIBITOR AND STATIN USE DECREASE RISK OF ESOPHAGEAL ADENOCARCINOMA AMONG INDIVIDUALS WITH BARRETT'S ESOPHAGUS: A SEER-MEDICARE ANALYSIS
Holli A. Loomans-Kropp et al.
GASTROENTEROLOGY (2020)
Risk Factors for Progression of Barrett's Esophagus to High Grade Dysplasia and Esophageal Adenocarcinoma
Swetha Kambhampati et al.
SCIENTIFIC REPORTS (2020)
Recent insights into the biology of Barrett's esophagus
Henry Badgery et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2020)
The role of esophagectomy in the management of Barrett's esophagus with high-grade dysplasia
Henry Badgery et al.
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES (2020)
Association between proton pump inhibitors use and risk of hip fracture: A general population-based cohort study
Jie Wei et al.
BONE (2020)
Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial)
Abhijeet Waghray et al.
DIGESTIVE DISEASES AND SCIENCES (2019)
Proton pump inhibitors and hypomagnesemia A meta-analysis of observational studies
Thawin Srinutta et al.
MEDICINE (2019)
Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans
M. C. Tan et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
The Epidemiology of Esophageal Adenocarcinoma
Helen G. Coleman et al.
GASTROENTEROLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial
Janusz A. Z. Jankowski et al.
LANCET (2018)
Systematic Review and Meta-analysis: Use of Statins Is Associated with a Reduced Incidence of Oesophageal Adenocarcinoma
Tom Thomas et al.
JOURNAL OF GASTROINTESTINAL CANCER (2018)
Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study
Prashanthi N. Thota et al.
JOURNAL OF DIGESTIVE DISEASES (2017)
Proton Pump Inhibitors Do Not Reduce the Risk of Esophageal Adenocarcinoma in Patients with Barrett's Esophagus: A Systematic Review and Meta-Analysis
Qiang Hu et al.
PLOS ONE (2017)
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort
Rajesh Krishnamoorthi et al.
GASTROINTESTINAL ENDOSCOPY (2016)
NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study
Gwen M. C. Masclee et al.
BMJ OPEN (2015)
Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Barrett's Esophagus
Jennifer L. Schneider et al.
DIGESTIVE DISEASES AND SCIENCES (2015)
Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients
F. Hvid-Jensen et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
710 Proton Pump Inhibitor Use but Not Statin Use Is Associated With Decreased Risk for High-grade Dysplasia and Esophageal Adenocarcinoma in Patients With Barrett's Esophagus: Results From a Large, Multicenter Cohort Study
Srinivas Gaddam et al.
GASTROENTEROLOGY (2014)
Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis
Siddharth Singh et al.
GUT (2014)
Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus
Florine Kastelein et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Barrett Esophagus and Risk of Esophageal Cancer A Clinical Review
Stuart Jon Spechler
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Meta-Analysis for Linear and Nonlinear Dose-Response Relations: Examples, an Evaluation of Approximations, and Software
Nicola Orsini et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2012)
Epidemiology and Natural History of Intestinal Metaplasia of the Gastroesophageal Junction and Barrett's Esophagus: A Population-Based Study
Kee Wook Jung et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Barrett's esophagus with high-grade dysplasia: Focus on current treatment options
Leonidas Lekakos et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2011)
Can Progression to Dysplasia in Barrett's Esophagus Be Prevented by Proton Pump Inhibitors?
Johnny Altawil et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
Andreas Stang
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2010)
Medications (NSAIDs, Statins, Proton Pump Inhibitors) and the Risk of Esophageal Adenocarcinoma in Patients With Barrett's Esophagus
Dang M. Nguyen et al.
GASTROENTEROLOGY (2010)
Persistent Reflux Symptoms in the Proton Pump Inhibitor Era: The Changing Face of Gastroesophageal Reflux Disease
Evan S. Dellon et al.
GASTROENTEROLOGY (2010)
Clopidogrel with or without Omeprazole in Coronary Artery Disease.
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
David Moher et al.
INTERNATIONAL JOURNAL OF SURGERY (2010)
Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
Dang M. Nguyen et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2009)
Potential Anti-inflammatory Effects of Proton Pump Inhibitors: A Review and Discussion of the Clinical Implications
Ramalinga R. Kedika et al.
DIGESTIVE DISEASES AND SCIENCES (2009)
American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease
Peter J. Kahrilas et al.
GASTROENTEROLOGY (2008)
Risk factors for the development of esophageal adenocarcinoma in Barrett's esophagus
Pieter J. F. de Jonge et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2006)
Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?
RC Fitzgerald
GUT (2005)
Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus
LC Hillman et al.
MEDICAL JOURNAL OF AUSTRALIA (2004)
Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenes
SI Abdalla et al.
CLINICAL CANCER RESEARCH (2004)
Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor
CR Haigh et al.
GASTROENTEROLOGY (2003)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Barrett's oesophagus, dysplasia and pharmacologic acid suppression
RC Fitzgerald et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2001)
The Vienna classification of gastrointestinal epithelial neoplasia
RJ Schlemper et al.
GUT (2000)
Share Paper
